Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
5-day change
1st Jan Change
22.54
USD
+1.26%
-2.80%
-36.85%
Presenter SpeechRobert Marcus (Analysts)Good morning, everyone. Happy to introduce our next se...
Transcript : AtriCure, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:15 AM
May. 14
Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating
May. 02
MT
Earnings Flash (ATRC) ATRICURE Reports Q1 Revenue $108.9M, vs. Street Est of $106.9M
May. 01
MT
Transcript : AtriCure, Inc., Q1 2024 Earnings Call, May 01, 2024
May. 01
AtriCure, Inc. Provides Earnings Guidance for the Year 2024
May. 01
CI
AtriCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 01
CI
Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32
Apr. 23
MT
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management
Apr. 18
CI
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing
Mar. 07
MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee
Feb. 27
CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating
Feb. 16
MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating
Feb. 16
MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating
Feb. 16
MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set
Feb. 15
MT
Transcript : AtriCure, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Feb. 15
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M
Feb. 15
MT
Atricure, Inc. Provides Earnings Guidance for 2024
Feb. 15
CI
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Feb. 15
CI
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating
Jan. 22
MT
Transcript : AtriCure, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
Jan. 10
AtriCure Reports Higher Preliminary Q4, 2023 Revenue; Issues 2024 Revenue Guidance; Shares Rise
Jan. 08
MT
AtriCure, Inc. and Its Wholly Owned Subsidiary, Atricure, LLC Enters into an Asset-Based Credit Agreement
Jan. 08
CI
Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024
Jan. 08
CI
AtriCure, Inc. Appoints Shlomi Nachman to its Board of Directors
Jan. 04
CI
AtriCure's Q3 Adjusted Loss Narrows, Revenue Rises; Full-Year Guidance Adjusted
Nov. 01
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
More about the company
Last Close Price
22.54
USD
Average target price
47.33
USD
Spread / Average Target
+110.00%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1